Logo

Now available
for DLBCL

The first Medicare-reimbursed MRD
assay for patients with DLBCL,
available as a CLIA-validated LDT.

$0 cost for Medicare patients—and with
no frequency restrictions.

LEARN MORE

MRD matters

MRD is the new standard in care for lymphoid malignancies

Routinely monitoring minimal residual disease (MRD) may improve patient prognostication and inform management decisions1

The real-world clinical value of MRD

Cancer centers across the country, from academic institutions to community practices, routinely:

Expert insights on MRD

Jeffrey Wolf, MD

Dr. Wolf discusses what he looks for when assessing MRD, including depth of detection and reliability.

This video was filmed by the Video Journal of Hematological Oncology (VJHemOnc) for use on VJHemonc.com. Adaptive Biotechnologies contributed to the video’s development and approval.

2021 ASCO clonoSEQ Industry Expert Theater: Allison Jacob, MS

Allison Jacob, medical director at Adaptive Biotechnologies, presents data that highlights the prognostic value of clonoSEQ® in lymphoid malignancies.

OncLive Peer Exchange

A panel of leading clinicians discuss the current and future role of MRD in clinical trials and clinical practice.

Content was developed independently by OncLive. This OncLive Peer Exchange was funded, in part, via a grant from Adaptive. Used with permission from OncLive.

ASH 2020 Product Theater: Lanny Kirsch, MD

Watch a live presentation from ASH 2020 where Dr. Kirsch reveals why clonoSEQ is a powerful tool for measuring MRD in real-world clinical management.

Ola Landgren, MD, PhD

Dr. Landgren offers insights on the role of MRD as a predictive marker of treatment benefit and as a clinical endpoint in new drug development.

VJHemOnc is an editorially independent video journal and does not endorse any products or companies associated with this content or connected materials.

Herve Avet-Loiseau, MD, PhD

Dr. Avet-Loiseau discusses the value of MRD measurement at 10-6 and the potential to use MRD negativity as a factor in multiple myeloma maintenance decisions.

This video was filmed and published by VJHemOnc. Adaptive Biotechnologies did not contribute to the video’s development and approval.

Nikhil Munshi, MD

Dr. Munshi discusses how MRD can detect treatment response deeper than traditional measures like complete response.

This video was filmed and published by VJHemOnc. Adaptive Biotechnologies did not contribute to the video’s development and approval.

Why MRD matters

Advanced MRD detection shows that complete response isn’t all that complete2

With therapeutic options available today, treatment responses are deeper than ever, but many patients who achieve a complete response (CR) eventually relapse. This illuminates the need to enhance traditional assessment techniques with sensitive tools like MRD.

Data from 609 multiple myeloma (MM) patients showed that MRD status was a better predictor of overall survival (OS) than CR.

About the study

A pooled analysis of 3 PETHEMA/GEM clinical trials (n = 609 newly diagnosed multiple myeloma patients), wherein 79% (n = 482) of patients were transplant eligible. MRD was assessed using 4-color and 8-color multiparameter flow cytometry (MFC).

About the study

A pooled analysis of 3 PETHEMA/GEM clinical trials (n = 609 newly diagnosed multiple myeloma patients), wherein 79% (n = 482) of patients were transplant eligible. MRD was assessed using 4-color and 8-color multiparameter flow cytometry (MFC).

MRD- vs CR: P < 0.001; CR vs nCR: P = 0.594; nCR vs PR: P = 0.912; PR vs < PR: P = 0.024.

An expert’s perspective on clonoSEQ MRD

“The disconnection between CR and long-term efficacy suggests that persistent disease remains undetected, and measuring deeper responses is necessary to predict and improve long-term outcomes.”3

—Dr. Avet-Loiseau

Why use clonoSEQ MRD technology?

clonoSEQ provides enhanced detection to inform clinical care

Conventional detection

Lurking cancer cells may go undetected.

Until recently, no FDA-cleared test offered a sensitivity of 10-6, an accurate quantification of disease burden, and the standardization necessary to provide clinicians with confidence in the results.1,4

Enhanced detection

Cancer cells that may have been
missed can now be detected.

The development of clonoSEQ has enabled precise identification and quantification of MRD in lymphoid malignancies. The deep sensitivity of clonoSEQ allows clinicians to assess a patient’s response to treatment and detect early relapse, which may inform decisions made throughout the course of disease.1,5


This page is intended for a US-based audience.

clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). CLL Clonality (ID) Tests will also produce an IGHV status result, which is provided as a CLIA-validated laboratory developed test (LDT) but which has not been cleared or approved by the FDA. Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA-validated LDT. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.

References

  • Ching T, et al. BMC Cancer. 2020;20:‌612.
  • Lahuerta J, et al. J Clin Oncol. 2017;35(25):29‌00-2‌910.
  • Avet-Loiseau H, et al. J Clin Oncol. 2021;39(10):11‌39-11‌49.